Oral Minoxidil for Chemotherapy-Induced Alopecia

This study reported that oral minoxidil improved hair density and had an acceptable safety profile in women with androgenetic alopecia.

This study concluded that oral minoxidil is an effective and well-tolerated alternative to topical minoxidil for healthy patients struggling with application-related compliance issues.

This study reviewed treatments for chemotherapy-induced hair loss, finding that scalp cooling is FDA-approved for prevention, while minoxidil and bimatoprost may aid post-chemotherapy regrowth. The authors emphasized tailored therapies and the potential utility of tools like trichoscopy and trichogram.

In this systematic review, oral minoxidil was found to be a safe and effective treatment for androgenetic alopecia and alopecia areata, with additional benefits for female pattern hair loss and other types of alopecia, although common side effects included hypertrichosis and postural hypotension.

This article discusses treatments for female pattern hair loss, highlighting that oral antiandrogens and topical minoxidil can effectively arrest progression and reverse miniaturization in many patients with mild-to-moderate cases, but it reports no new clinical results.

This review discusses chemotherapy-induced alopecia, highlighting its pathogenesis, clinical patterns, and current therapeutic approaches, with no new clinical results reported.

This review discusses chemotherapy-induced hair loss, highlighting that topical minoxidil can lessen its severity or duration but not prevent it, and reports no new clinical results.